![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/afec978f479975cf7f33737280a29c6f130bfb41-1264x696.png?fit=crop&auto=format)
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney Cancer
Ubamatamab in combination with anti-PD-inhibition may enhance the immune response in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma, said Pavlos Msaouel, MD, PhD. CancerNetwork® spoke with Msaouel, an …